Related Experiment Video
Updated: Jul 18, 2026
07:30
Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
Published on: November 21, 2012
NAN-190, a possible specific antagonist for methamphetamine
O T Ginawi1, A A Al-Majed, A K Al-Suwailem
1Department of Pharmacology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia. otginawi@hotmail.com
Regulatory Toxicology and Pharmacology : RTP
|February 9, 2005
Summary
NAN-190, a 5-HT(1A) receptor antagonist, effectively blocked methamphetamine's effects on mouse behavior, including hyperactivity, appetite loss, and temperature changes. This suggests a role for serotonin in mediating methamphetamine's actions.
Area of Science:
- Neuropharmacology
- Behavioral Neuroscience
Background:
- Methamphetamine exerts diverse effects, including locomotor stimulation, anorexia, analgesia, and hyperthermia.
- Serotonergic (5-HT) pathways are implicated in modulating these methamphetamine-induced effects, alongside catecholaminergic systems.
Purpose of the Study:
- To investigate the role of the 5-HT(1A) receptor in mediating methamphetamine's effects.
- To evaluate NAN-190, a selective 5-HT(1A) receptor antagonist, as a potential blocker of methamphetamine's actions.
Main Methods:
- Male mice were administered methamphetamine and NAN-190 (a 5-HT(1A) receptor antagonist) via intraperitoneal injection.
- Behavioral assessments included locomotor activity, food intake, body temperature, and antinociception (writhing test).
Main Results:
- NAN-190 significantly antagonized methamphetamine-induced locomotor activity, anorexia, and hyperthermia in mice.
- NAN-190 also antagonized the antinociceptive effect of methamphetamine in the writhing test.
- NAN-190 alone did not alter locomotor activity, food intake, body temperature, or antinociception.
Conclusions:
- The findings suggest a significant role for serotonergic mechanisms, specifically involving the 5-HT(1A) receptor, in mediating methamphetamine's effects.
- NAN-190 demonstrates potential as an antagonist for methamphetamine, highlighting the involvement of 5-HT(1A) receptors in methamphetamine's complex pharmacology.
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...